This post was written by Paul Sheives.

FDA is rolling out phase II of the FDA’s Transparency Initiative with the issuance of 21 draft proposals intended to expand disclosure of information while maintaining confidentiality of trade secrets and individually identifiable patient information. These proposals are based on over 1500 comments previously submitted by industry and two public meetings aimed to identify types of information that should be more transparent at FDA. Written comments will be accepted by FDA until July 20, 2010.